Trial · NCT05317416
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416, Phase 3, Active not recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant. Trials, record NCT05317416. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05317416
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
- NCT number
- NCT05317416
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 854 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab, Lenalidomide, Lenalidomide, Elranatamab
- First posted
- 2022-04-07
- Last updated
- 2026-04-16
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival | Assessed for up to approximately 5 years | Progression Free Survival assessed by Blinded Independent Central review per IMWG response criteria |
| Secondary | Minimal residual disease Negative rate | 12 months after randomization | per IMWG as assessed via next generation sequencing (NGS) |
| Secondary | Progression Free Survival by BICR per IMWG in IMWG 2025 high-risk participants | Assessed up to approximately 5 years | Progression Free Survival by BICR per IMWG in IMWG 2025 high-risk participants |
| Secondary | PFS by BICR per IMWG in IMWG 2025 standard-risk participant | Assessed up to approximately 5 years | PFS by BICR per IMWG in IMWG 2025 standard-risk participant |
| Secondary | Overall Survival | Assessed for up to approximately 5 years | Defined as the time from randomization until death due to any cause |
| Secondary | MRD-negative rate per IMWG 2025 | 12 months after randomization | Assessed via NGS in IMWG 2025 subgroups |
| Secondary | Sustained MRD negative rate | 24 months after randomization | Sustained Minimal Residual Disease negative rate per IMWG criteria as assessed via Next Generation Sequencing |
| Secondary | Progression Free Survival | Assessed for up to approximately 5 years | Progression Free Survival by investigator per IMWG response criteria |
| Secondary | Overall minimal residual disease negative rate | Assessed for up to approximately 5 years | Minimal residual disease negative rate per IMWG criteria |
| Secondary | Duration of minimal residual disease negativity | Assessed for up to approximately 5 years | Minimal residual disease negativity per IMWG criteria |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05317416
GET https://conductscience.org/api/trials/v1/NCT05317416/registered?page=2